secwatch.observer — SEC 8-K summary
======================================

Issuer:     Parabilis Medicines, Inc. (PBLS)
CIK:        0001657677
Form:       8-K
Filed at:   2026-08-25T20:10:15+00:00
Accession:  0001193125-26-365132
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Parabilis Medicines appoints Craig Tendler to board as independent Class II director
--------------------------------------------------------------------------------

- Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.
- Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.
- Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.
- Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/0001193125-26-365132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/ck0001657677-20260822.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-365132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer